Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8507705 | 0.90 | AGTR1 (0.56) | AGTR1AGTR2 | |
| SCHEMBL27406325 | 0.89 | AGTR1 (0.55) | AGTR1AGTR2 | |
| SCHEMBL27382399 | 0.88 | AGTR1 (0.54) | AGTR1AGTR2 | |
| SCHEMBL27405616 | 0.88 | AGTR1 (0.54) | AGTR1AGTR2 | |
| SCHEMBL951175 | 0.87 | AGTR1 (0.66) | AGTR1AGTR2 | |
| SCHEMBL9128122 | 0.87 | AGTR1 (0.54) | AGTR1AGTR2 | |
| SCHEMBL9122452 | 0.87 | AGTR1 (0.53) | AGTR1AGTR2 | |
| SCHEMBL7995850 | 0.87 | AGTR1 (0.52) | AGTR1AGTR2 | |
| SCHEMBL27532043 | 0.86 | AGTR1 (0.53) | AGTR1AGTR2 | |
| SCHEMBL9125809 | 0.86 | AGTR1 (0.52) | AGTR1AGTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 86 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110054186-A1 | PROCESS FOR EPROSARTAN INTERMEDIATE | HETERO RESEARCH FOUNDATION (IN) | 2011-03-03 | — | — | US | claimed |
| EP-2257540-A2 | IMPROVED PROCESS FOR EPROSARTAN INTERMEDIATE | Hetero Research Foundation (IN) | 2010-12-08 | — | — | EP | claimed |
| US-20100137613-A1 | PROCESS FOR EPROSARTAN | HETERO DRUGS LIMITED (IN) | 2010-06-03 | — | — | US | claimed |
| WO-2009122421-A2 | IMPROVED PROCESS FOR EPROSARTAN INTERMEDIATE | HETERO RESEARCH FOUNDATION (IN) | 2009-10-08 | — | — | WO | claimed |
| EP-2097408-A1 | IMPROVED PROCESS FOR EPROSARTAN | Hetero Drugs Limited (IN) | 2009-09-09 | — | — | EP | claimed |
| WO-2009084028-A2 | IMPROVED PROCESS FOR MANUFACTURING ANHYDROUS (E)-3-[2-BUTYL-1- {(4-CARBOXYPHENYL) METHYL}-1H-IMIDAZOLE-5-YL]-(THIOPHEN-2- YLMETHYL)PROP-2-ENOIC ACID METHANE SULFONATE | NEULAND LABORATORIES LTD (IN) | 2009-07-09 | — | — | WO | claimed |
| WO-2008078330-A1 | IMPROVED PROCESS FOR EPROSARTAN | HETERO DRUGS LIMITED (IN) | 2008-07-03 | — | — | WO | claimed |
| US-8865755-B2 | Dual-acting antihypertensive agents | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2014-10-21 | — | — | US | disclosed |
| US-8865755-B2 | Dual-acting antihypertensive agents | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2014-10-21 | — | — | US | disclosed |
| US-8865755-B2 | Dual-acting antihypertensive agents | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2014-10-21 | — | — | US | disclosed |
| US-20130210874-A1 | DUAL-ACTING ANTIHYPERTENSIVE AGENTS | THERAVANCE, INC. (US) | 2013-08-15 | — | — | US | disclosed |
| US-20130210874-A1 | DUAL-ACTING ANTIHYPERTENSIVE AGENTS | THERAVANCE, INC. (US) | 2013-08-15 | — | — | US | disclosed |
| US-20130210874-A1 | DUAL-ACTING ANTIHYPERTENSIVE AGENTS | THERAVANCE, INC. (US) | 2013-08-15 | — | — | US | disclosed |
| US-5177096-A | Angiotensin II receptor antagonist | SMITHKLINE BEECHAM CORPORATION (US) | 1993-01-05 | — | — | US | disclosed |
| WO-1992002510-A1 | SUBSTITUTED [1H-IMIDAZOL-5-YL]ALKANOIC ACIDS | SMITHKLINE BEECHAM CORPORATION (US) | 1992-02-20 | — | — | WO | disclosed |
| EP-0425211-A1 | Substituted 5-((tetrazolyl)alkenyl)-imidazoles | SMITHKLINE BEECHAM CORPORATION (US) | 1991-05-02 | — | — | EP | disclosed |
| CN-1048039-A | Imidazolyl-alkenoic acids | SMITHKLINE BEECHAM CORP (US) | 1990-12-26 | — | — | CN | disclosed |
| CN-1048038-A | IMIDAZOLYL-ALKENOIC ACIDS | SMITHKLINE BEECHAM CORP (US) | 1990-12-26 | — | — | CN | disclosed |
| EP-0403158-A2 | Imidazolyl-alkenoic acids | SMITHKLINE BEECHAM CORPORATION (US) | 1990-12-19 | — | — | EP | disclosed |
| EP-0403159-A2 | Imidazolyl-alkenoic acids | SMITHKLINE BEECHAM CORPORATION (US) | 1990-12-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110054186-A1 | PROCESS FOR EPROSARTAN INTERMEDIATE | PTGER1, PTGER4, PDGFRA | AGTR1 250/4885AGTR2 159/4885 |
| US-20130210874-A1 | DUAL-ACTING ANTIHYPERTENSIVE AGENTS | AGTR1, REN, AGTR2 | AGTR1 1/4885AGTR2 3/4885 |
| US-20100137613-A1 | PROCESS FOR EPROSARTAN | PTMA, PTGER1, PDGFRA | AGTR1 289/4885AGTR2 213/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.